Elan announces launch of extended release Ampyra in U.S.

Following its approval earlier this year, Elan Drug Technologies has announced the launch of Ampyra (dalfampridine) by Acorda Therapeutics in the U.S. as a treatment to improve walking in patients with multiple sclerosis. The first NDA approved and launched incorporating Elan's MXDAS technology, Ampryra was developed using a hydrophilic matrix, which controls the rate of release of dalfampridine through a process of diffusion and erosion in the gastrointestinal tract. Release

Suggested Articles

The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.